Skip to main content
GileadRevenue

Generic Lenacapavir Wins FDA Tentative Approval, but U.S. Yeztugo Users Can’t Switch Yet

Source: Autobound Signal API · 74 signals tracked for Gilead · updated

Get Gilead's live signals in Claude or ChatGPT, or by API

AskWhat changed at Gilead this week? Use Autobound signals for gilead.com.

What happened

Gilead Sciences generated $305 million in third-quarter revenue from its HIV prevention drug Yeztugo.

Source

Article excerpt

The FDA has granted tentative approval to the first generic injectable lenacapavir for HIV prevention, made by India’s Dr. Reddy’s Laboratories, the company and its partners announced Monday, Nov. 2. Lenacapavir is the drug Gilead Sciences sells for prevention in the U.S. as Yeztugo, the twice-yearly PrEP shot. Dr. Reddy’s version will cost $40 per person per year in the 120 low- and middle-income countries covered by Gilead’s license, Unitaid said, a price “in line with oral PrEP.” It cannot be sold in the U.S. Yeztugo is still under patent, and its U.S. list price is $28,218 a year, The Associated Press reported. “For someone at risk of HIV, taking a pill every day to prevent a disease they don’t have is a hard thing to ask,” said Neil Buddy Shah, CEO of the Clinton Health Access Initiative. “Two injections a year, of a product that is almost 100% effective at preventing HIV, changes that entirely.” People don’t always take a daily pill, “and if you do not take it, you cannot get protected against HIV,” Carmen Pérez Casas, Unitaid’s HIV lead, told the AP. “With lenacapavir, we are much more hopeful.” A tentative approval “does not allow the applicant to market the generic drug product,” the FDA’s glossary says. Final approval waits until “all patent or exclusivity issues have been resolved.” (So no, your pharmacist can’t swap in a $40 version.) The partners’ release...

Keep reading with a free account

The rest of this article, and every signal for Gilead, is in your free account.

Extracted from this sentence

The shot made $305 million in the third quarter, and Johanna Mercier, Gilead’s chief commercial and corporate affairs officer, put its pharmacy-benefit coverage at “about 70% or so,” Gayety reported Oct. 30.

Extracted by Autobound

From the Signal API record
Event
Revenue

What this signalsRevenue results often set the next budget cycle.

Amount named
$305M

The full record

From the Signal API record

Numbers

Amount named in the story
$305M

Extraction

Confidence
85%
Detected
Nov 3, 2026
signal_type
news
signal_subtype
has_revenue

Use this data

Get every revenue signal for Gilead and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Gilead this week?”

  2. Send it to your own tools

    The Signal API returns revenue signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/d25cb50f-124f-4b9d-b5c8-b948ce4935fa returns this record as JSON. POST /v1/companies/enrich returns every signal for gilead.com.

{
  "signal_id": "d25cb50f-124f-4b9d-b5c8-b948ce4935fa",
  "signal_type": "news",
  "signal_subtype": "has_revenue",
  "detected_at": "2026-11-03T16:48:13+00:00",
  "company": {
    "name": "Gilead",
    "domain": "gilead.com"
  },
  "data": {
    "url": "https://gayety.com/generic-lenacapavir-yeztugo-fda-tentative-approval",
    "title": "Generic Lenacapavir Wins FDA Tentative Approval, but U.S. Yeztugo Users Can’t Switch Yet - Gayety",
    "excerpt": "The FDA has granted tentative approval to the first generic injectable lenacapavir for HIV prevention, made by India’s Dr. Reddy’s Laboratories, the company and its partners announced Monday, Nov. 2. Lenacapavir is the drug Gilead Sciences sells for prevention in the U.S. as Yeztugo, the twice-yearly PrEP shot. Dr. Reddy’s version will cost $40 per person per year in the 120 low- and middle-income countries covered by Gilead’s license, Unitaid said , a price “in line with oral PrEP.” It cannot be sold in the U.S. Yeztugo is still under patent, and its U.S. list price is $28,218 a year, The Associated Press reported . “For someone at risk of HIV, taking a pill every day to prevent a disease they don’t have is a hard thing to ask,” said Neil Buddy Shah, CEO of the Clinton Health Access Initiative . “Two injections a year, of a product that is almost 100% effective at preventing HIV, changes that entirely.” People don’t always take a daily pill, “and if you do not take it, you cannot get protected against HIV,” Carmen Pérez Casas, Unitaid’s HIV lead, told the AP. “With lenacapavir, we are much more hopeful.” A tentative approval “does not allow the applicant to market the generic drug product,” the FDA’s glossary says. Final approval waits until “all patent or exclusivity issues have been resolved.” (So no, your pharmacist can’t swap in a $40 version.) The partners’ release said...",
    "summary": "Gilead Sciences generated $305 million in third-quarter revenue from its HIV prevention drug Yeztugo.",
    "planning": false,
    "image_url": "https://gayety.com/wp-content/uploads/2026/11/lenacapavir-access-packaging-featured.jpg",
    "confidence": 0.85,
    "published_at": "2026-11-03T16:48:13Z",
    "article_sentence": "The shot made $305 million in the third quarter, and Johanna Mercier, Gilead’s chief commercial and corporate affairs officer, put its pharmacy-benefit coverage at “about 70% or so,” Gayety reported Oct. 30.",
    "amount_normalized": 305000000
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.